Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iobenguane I-131 + lutetium Lu 177 dotatate
- Development stage
- Unknown
- Lead developer
- Lantheus
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination refers to the use of two radiopharmaceuticals: **iobenguane I-131 (also known as Azedra, iodine I 131-metaiodobenzylguanidine, or 131I-MIBG)** and **lutetium Lu 177 dotatate (also known as Lutathera, Lu-177 dotatate)**. Iobenguane I-131 is a norepinephrine analog taken up by adrenergic tissues, delivering targeted beta radiation to tumors of neural crest origin that express the norepinephrine transporter, such as pheochromocytoma and paraganglioma. Lutetium Lu 177 dotatate is a somatostatin analog conjugated to radioactive lutetium, targeting tumors that overexpress the somatostatin receptor (notably gastroenteropancreatic neuroendocrine tumors), emitting beta and gamma rays to induce cell death through DNA damage. Both drugs are radiopharmaceuticals used primarily in oncology for specific neuroendocrine malignancies, and combination regimens are being studied for enhanced efficacy in eligible populations[1][7][5].
- Other names
- iodine I 131-metaiodobenzylguanidine131I-MIBGLu-177 dotatateLu177 dotatateLu 177 dotatate
02
Targets
NET (Norepinephrine Transporter)SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on iobenguane I-131 + lutetium Lu 177 dotatate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iobenguane I-131 + lutetium Lu 177 dotatate.